{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,16]],"date-time":"2026-03-16T15:21:50Z","timestamp":1773674510109,"version":"3.50.1"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2021,6,2]],"date-time":"2021-06-02T00:00:00Z","timestamp":1622592000000},"content-version":"vor","delay-in-days":1,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drug Saf"],"published-print":{"date-parts":[[2021,6]]},"DOI":"10.1007\/s40264-021-01065-z","type":"journal-article","created":{"date-parts":[[2021,6,2]],"date-time":"2021-06-02T03:41:50Z","timestamp":1622605310000},"page":"699-709","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Signal Detection and Methodological Limitations in a Real-World Registry: Learnings from the Evaluation of Long-Term Safety Analyses in PSOLAR"],"prefix":"10.1007","volume":"44","author":[{"given":"Robert","family":"Bissonnette","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alice B.","family":"Gottlieb","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard G.","family":"Langley","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Craig L.","family":"Leonardi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kim A.","family":"Papp","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David M.","family":"Pariser","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jonathan","family":"Uy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kim Parnell","family":"Lafferty","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wayne","family":"Langholff","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Steven","family":"Fakharzadeh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jesse A.","family":"Berlin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emily S.","family":"Brouwer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew J.","family":"Greenspan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bruce E.","family":"Strober","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,6,2]]},"reference":[{"key":"1065_CR1","doi-asserted-by":"publisher","first-page":"1100","DOI":"10.1111\/jdv.13634","volume":"30","author":"L Eissing","year":"2016","unstructured":"Eissing L, Rustenbach SJ, Krensel M, et al. Psoriasis registries worldwide: systematic overview on registry publications. J Eur Acad Dermatol Venereol. 2016;30:1100\u20136.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"1065_CR2","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1080\/09546634.2017.1328549","volume":"28","author":"M Amin","year":"2017","unstructured":"Amin M, No DJ, Wu JJ. Review of U.S. registries for psoriasis. J Dermatol Treat. 2017;28:687\u2013701.","journal-title":"J Dermatol Treat."},{"key":"1065_CR3","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1080\/09546634.2018.1506084","volume":"30","author":"M Amin","year":"2019","unstructured":"Amin M, Lee EB, Bhutani T, Wu JJ. Review of European registries for psoriasis. J Dermatol Treat. 2019;30:227\u201336.","journal-title":"J Dermatol Treat."},{"key":"1065_CR4","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1159\/000096196","volume":"213","author":"M Schmitt-Egenolf","year":"2006","unstructured":"Schmitt-Egenolf M. Psoriasis therapy in real life: the need for registries. Dermatology. 2006;213:327\u201330.","journal-title":"Dermatology"},{"key":"1065_CR5","first-page":"1210","volume":"11","author":"KA Papp","year":"2012","unstructured":"Papp KA, Strober B, Augustin M, on behalf of the PSOLAR investigators and Steering Committee, et al. PSOLAR: design, utility, and preliminary results of a prospective, international, disease-based registry of patients with psoriasis who are receiving, or are candidates for, conventional systemic treatments or biologic agents. J Drugs Derm. 2012;11:1210\u20137.","journal-title":"J Drugs Derm."},{"key":"1065_CR6","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1111\/bjd.13013","volume":"171","author":"AB Kimball","year":"2014","unstructured":"Kimball AB, Leonardi C, Stahle M, et al. Demography, baseline disease characteristics and treatment history of patients with psoriasis enrolled in a multicenter, prospective, disease-based registry (PSOLAR). Br J Dermatol. 2014;171:137\u201347.","journal-title":"Br J Dermatol."},{"key":"1065_CR7","unstructured":"Bissonnette R, Langholff W. Evaluation of risk of major adverse cardiovascular events with biologic therapy in patients with psoriasis (errata). J Drugs Dermatol. 2020;19:e28-e32. https:\/\/jddonline.com\/articles\/dermatology\/S1545961620P0566X. Accessed 2 Apr 2021."},{"key":"1065_CR8","unstructured":"Papp KA, Langholff W. Safety surveillance for ustekinumab and other psoriasis treatments from the Psoriasis Longitudinal Assessment and Registry (PSOLAR) (errata). J Drugs Dermatol. 2020;19:e33-e34. https:\/\/jddonline-com.ezjnj02.infotrieve.com\/articles\/dermatology\/S1545961620P0571X. Accessed 2 Apr 2021."},{"key":"1065_CR9","unstructured":"Gottlieb AB, Langolff W. Safety observations in 12095 patients with psoriasis enrolled in an international registry (PSOLAR): experience with infliximab and other systemic and biologic therapies (errata). J Drugs Dermatol. 2020;19:e35-e36. https:\/\/jddonline-com.ezjnj02.infotrieve.com\/articles\/dermatology\/S1545961620P0571X. Accessed 2 Apr 2021."},{"key":"1065_CR10","doi-asserted-by":"publisher","first-page":"2054","DOI":"10.1093\/eurheartj\/ehr285","volume":"33","author":"O Ahlehoff","year":"2012","unstructured":"Ahlehoff O, Gislason GH, Jorgensen CH, et al. Psoriasis and risk of atrial fibrillation and ischaemic stroke: a Danish nationwide cohort study. Eur Heart J. 2012;33:2054\u201364.","journal-title":"Eur Heart J."},{"key":"1065_CR11","doi-asserted-by":"publisher","first-page":"2411","DOI":"10.1038\/jid.2009.112","volume":"129","author":"JM Gelfand","year":"2009","unstructured":"Gelfand JM, Dommasch ED, Shin DB, et al. The risk of stroke in patients with psoriasis. J Investig Dermatol. 2009;129:2411\u20138.","journal-title":"J Investig Dermatol."},{"key":"1065_CR12","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/pds.3334","volume":"22","author":"ES Johnson","year":"2013","unstructured":"Johnson ES, Bartman BA, Briesacher BA, et al. The incident user design in comparative effectiveness research. Pharmacoepidem Drug Safety. 2013;22:1\u20136.","journal-title":"Pharmacoepidem Drug Safety."},{"key":"1065_CR13","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1007\/s40471-015-0053-5","volume":"2","author":"JL Lund","year":"2015","unstructured":"Lund JL, Richardson DB, Sturmer T. The active comparator, new user study design in pharmacoepidemiology: historical foundations and contemporary application. Curr Epidemiol Rep. 2015;2:221\u20138.","journal-title":"Curr Epidemiol Rep."},{"key":"1065_CR14","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1093\/aje\/kwr301","volume":"175","author":"G Danaei","year":"2012","unstructured":"Danaei G, Tavakkoli M, Hernan MA. Bias in observational studies of prevalent users: lessons for comparative effectiveness research from a meta-analysis of statins. Am J Epidemiol. 2012;175:250\u201362.","journal-title":"Am J Epidemiol."},{"key":"1065_CR15","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1111\/joim.12197","volume":"275","author":"T Sturmer","year":"2014","unstructured":"Sturmer T, Wyss R, Glynn RJ, Brookhart MA. Propensity scores for confounder adjustment when assessing the effects of medical interventions using nonexperimental study designs. J Intern Med. 2014;275:570\u201380.","journal-title":"J Intern Med."},{"key":"1065_CR16","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1093\/aje\/kwq198","volume":"172","author":"T Sturmer","year":"2010","unstructured":"Sturmer T, Rothman KJ, Avorn J, Glynn RJ. Treatment effects in the presence of unmeasured confounding: dealing with observations in the tails of the propensity score distribution\u2014a simulation study. Am J Epidemiol. 2010;172:843\u201354.","journal-title":"Am J Epidemiol."},{"key":"1065_CR17","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1093\/aje\/kwj047","volume":"163","author":"T Kurth","year":"2006","unstructured":"Kurth T, Walker AM, Glynn RJ, et al. Results of multivariable logistic regression, propensity matching, propensity adjustment, and propensity-based weighting under conditions of nonuniform effect. Am J Epidemiol. 2006;163:262\u201370.","journal-title":"Am J Epidemiol."},{"key":"1065_CR18","unstructured":"Stelara Prescribing Information. Horsham, PA; Janssen Biotech, Inc; July 2020."},{"key":"1065_CR19","unstructured":"Humira Prescribing Information. North Chicago, IL: AbbVie Inc.; March 2020"},{"key":"1065_CR20","first-page":"1002","volume":"16","author":"R Bissonnette","year":"2017","unstructured":"Bissonnette R, Kerdel F, Naldi L, et al. Evaluation of risk of major adverse cardiovascular events with biologic therapy in patients with psoriasis. J Drugs Dermatol. 2017;16:1002\u201313.","journal-title":"J Drugs Dermatol."},{"key":"1065_CR21","doi-asserted-by":"publisher","first-page":"845-54.e5","DOI":"10.1016\/j.jaad.2017.07.013","volume":"77","author":"D Fiorentino","year":"2017","unstructured":"Fiorentino D, Ho V, Lebwohl MG, et al. Risk of malignancy with systemic psoriasis treatment in the Psoriasis Longitudinal Assessment Registry. J Am Acad Dermatol. 2017;77:845-54.e5.","journal-title":"J Am Acad Dermatol."},{"key":"1065_CR22","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/j.jaad.2020.08.032","volume":"84","author":"RG Langley","year":"2021","unstructured":"Langley RG, Poulin Y, Srivastava B, et al. Reduced risk of mortality associated with systemic psoriasis treatment in the Psoriasis Longitudinal Assessment and Registry (PSOLAR): A nested case-control analysis. J Am Acad Dermatol. 2021;84:60\u20139.","journal-title":"J Am Acad Dermatol."},{"key":"1065_CR23","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1001\/jamadermatol.2015.0718","volume":"151","author":"RE Kalb","year":"2015","unstructured":"Kalb RE, Fiorentino DF, Lebwohl MG, et al. Risk of serious infection with biologic and systemic treatment of psoriasis: results from the Psoriasis Longitudinal Assessment and Registry (PSOLAR). JAMA Dermatol. 2015;151:961\u20139.","journal-title":"JAMA Dermatol."},{"key":"1065_CR24","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1111\/jdv.14583","volume":"32","author":"CI Busard","year":"2018","unstructured":"Busard CI, Cohen AD, Wolf P, et al. Biologics combined with conventional systemic agents or phototherapy for the treatment of psoriasis: real-life data from PSONET registries. J Eur Acad Dermatol Venereol. 2018;32:245\u201353.","journal-title":"J Eur Acad Dermatol Venereol."},{"key":"1065_CR25","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1159\/000371881","volume":"230","author":"F Hjalte","year":"2015","unstructured":"Hjalte F, Steen Carlsson K, Schmitt-Egenolf M. Real-world outcome anlaysis of continuously and intermittently treated patients with moderate to severe psoriasis after switching to a biologic agent. Dermatology. 2015;230:347\u201353.","journal-title":"Dermatology"},{"key":"1065_CR26","doi-asserted-by":"publisher","first-page":"1410","DOI":"10.1111\/bjd.15531","volume":"177","author":"IYK Iskandar","year":"2017","unstructured":"Iskandar IYK, Ashcroft DM, Warren RB, et al. Comparative effectiveneess of biological therapies on improvements in quality of life in patients with psoriasis. Br J Dermatol. 2017;177:1410\u201321.","journal-title":"Br J Dermatol."},{"key":"1065_CR27","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1016\/j.jaad.2012.10.055","volume":"68","author":"AB Kimball","year":"2013","unstructured":"Kimball AB, Pariser D, Yamauchi PS, et al. OBSERVE -5 interim analysis: an observational postmarketing safety registry of etanercept for the treatment of psoriasis. J Am Acad Dermatol. 2013;68:756\u201364.","journal-title":"J Am Acad Dermatol."},{"key":"1065_CR28","doi-asserted-by":"publisher","first-page":"858","DOI":"10.1111\/jdv.12688","volume":"29","author":"C Medina","year":"2015","unstructured":"Medina C, Carretero G, Ferrandiz C, et al. Safety of classic and biologic systemic therapies for the treatment of psoriasis in elderly: an observational study from national BIOBADADERM registry. J Eur Acad Dermatol Venereol. 2015;29:858\u201364.","journal-title":"J Eur Acad Dermatol Venereol."},{"key":"1065_CR29","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1007\/s13555-017-0198-x","volume":"7","author":"A Menter","year":"2017","unstructured":"Menter A, Thaci D, Wu J, et al. Long-term safety and effectiveness of adalimumab for moderate to severe psoriasis: results from 7-year interim analysis of the ESPRIT registry. Dermatol Ther (Heidelb). 2017;7:365\u201381.","journal-title":"Dermatol Ther (Heidelb)."},{"key":"1065_CR30","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1007\/s00403-015-1593-8","volume":"307","author":"K Reich","year":"2015","unstructured":"Reich K, Mrowietz U, Radtke MA, et al. Drug safety of systemic treatments for psoriasis: results from The German Psoriasis Registry PsoBest. Arch Dermatol Res. 2015;307:875\u201383.","journal-title":"Arch Dermatol Res."}],"container-title":["Drug Safety"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40264-021-01065-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40264-021-01065-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40264-021-01065-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,7]],"date-time":"2021-06-07T11:38:56Z","timestamp":1623065936000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40264-021-01065-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6]]},"references-count":30,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2021,6]]}},"alternative-id":["1065"],"URL":"https:\/\/doi.org\/10.1007\/s40264-021-01065-z","relation":{},"ISSN":["0114-5916","1179-1942"],"issn-type":[{"value":"0114-5916","type":"print"},{"value":"1179-1942","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,6]]},"assertion":[{"value":"19 March 2021","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 June 2021","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"PSOLAR was supported by Janssen Scientific Affairs, LLC.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Robert Bissonnette is an Advisory Board Member, Consultant, Speaker, Investigator for, and\/or received honoraria or grants from AbbVie, Almirall, Anaptys Bio, Arcutis, Arista, Bausch Health\/Valeant, Boehringer Ingelheim, Boston Pharma, Bristol-Myers Squibb, Dermavant, Eli Lilly, Escalier, Janssen, Kineta, Kyowa Kirin, LEO Pharma, Pfizer, Regeneron, Sienna and UCB. Alice B. Gottlieb has received honoraria as an advisory board member and consultant for Avotres Therapeutics, Belersdorf, Boehringer Ingelheim, Bristol-Meyers Squibb Co., Incyte, Janssen, Leo Pharma, Eli Lilly, Novartis, Sun Pharmaceutical Industries, Inc., UCB, and Xbiotech (only stock options that she has not used); and has received research\/educational grants from Boehringer Ingelheim, Incyte, Janssen, Novartis, UCB, Xbiotech, and Sun Pharma. Richard G. Langley has received honoraria or grants as principal investigator, scientific advisory board member, and lecturer for AbbVie, Amgen, Celgene, Leo, Merck, Novartis, and Pfizer; and as principal investigator and scientific advisory board member for Boehringer Ingelheim, Lilly, and UCB. Craig L. Leonardi has received honoraria or grants as an consultant\/advisory board member for AbbVie, Amgen, Boehringer-Ingelheim, Dermira, Eli Lilly, Janssen, Leo, Pfizer, Sandoz, UCB and Vitae; as an investigator for Actavis, AbbVie, Allergan, Amgen, Boehringer-Ingelheim, Celgene, Coherus, Cellceutix, Corrona, Dermira, Eli Lilly, Galderma, Glenmark, Janssen, Leo Pharma, Merck, Novartis, Novella, Pfizer, Sandoz, Sienna, Stiefel, UCB and Wyeth; and as a speaker for AbbVie, Amgen, Celgene, Eli Lilly, Janssen, Novartis, Ortho Dermatologics, Sun Pharmaceuticals, and UCB. Kim A. Papp has received honoraria and\/or grants from AbbVie, Akros, Amgen, Arcutis, Astellas, AstraZeneca, Avilion, Baxalta, Boehringer Ingelheim, Bristol-Myers Squibb, Canfite, Celgene, Centocor, Coherus, Dermira, Dow Pharma, Eli Lilly and Company, Forward Pharma, Galderma, Genentech, Gilead, GlaxoSmithKline, Janssen, Kyowa Hakko Kirin, LEO, MedImmune, Meiji Seika Pharma, Merck (MSD), Merck-Serono, Mitsubishi Pharma, Moberg Pharma, Novartis, Pfizer, PRCL Research, Regeneron, Roche, Sanofi Aventis\/Genzyme, Samsung Bioepsis, Sun Pharma, Takeda, UCB Pharma, and Valeant\/Bausch Health. David M. Pariser has received honoraria or grants\/research funding as an investigator at Abbott Laboratories, Almirall, Amgen, AOBiome LLC, Asana Biosciences LLC, Bickel Biotechnology, Celgene Corporation, Dermavent Sciences, Dermira, Eli Lilly and Co., Leo Pharma, Menlo Therapuetics, Merck & Co., Novartis Pharmaceuticals, Novo Nordisk A\/S, Ortho Dermatologics, Pfizer Inc., Regeneron, Stiefel (a GSK company), and Valeant Pharmaceuticals International; as an consultant at Atacama Therapeutics, Bickel Biotechnology, Biofrontera AG, BMS, Celgene, Dermira, Leo Pharma, Novartis, Pfizer, Regeneron, Sanofi, TDM SurgiTech, TheraVida, and Valeant Pharmaceuticals International; as an advisory board member at Pfizer; and as a Data Safety Monitoring Board member at BMS. Jonathan Uy, Kim Parnell Lafferty, Wayne Langholff, Steven Fakharzadeh, Emily S. Brouwer, and Andrew J. Greenspan are employees of Janssen, of which Johnson & Johnson is the parent company, and own stock or stock options in Johnson & Johnson. Jesse A. Berlin is an employee of Johnson & Johnson and owns stock or stock options in Johnson & Johnson. Bruce E. Strober has received honoraria or research grants as a consultant for AbbVie, Almirall, Amgen, Arcutis, Arena, Aristea, Boehringer Ingelheim, Bristol-Myers-Squibb, Celgene, Dermavant, Dermira, Equillium, Janssen, Leo, Eli Lilly, Meiji Seika Pharma, Mindera, Novartis, Pfizer, GlaxoSmithKline, UCB Pharma, Sun Pharma, Ortho Dermatologics, Regeneron, and Sanofi-Genzyme; as a speaker for AbbVie, Amgen, Eli Lilly, Janssen, and Ortho Dermatologics; as scientific director for the Corrona Psoriasis Registry; as an investigator for Dermavant, AbbVie, Corrona Psoriasis Registry, Dermira, Cara, and Novartis; and as Editor-in-Chief at the <i>Journal of Psoriasis and Psoriatic Arthritis.<\/i>","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"The registry protocol was approved by an Institutional Review Board or Ethics Committee at all study sites.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Written informed consent was provided by all patients before participating in the study.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"All authors approved the final version of the manuscript and agreed to submit for publication.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The data sharing policy of Janssen Pharmaceutical Companies of Johnson & Johnson is available at .","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data availability statement"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"RB, RGL, CLL, KAP, DMP, WL, and BS contributed to the study conception and design of the registry. KAP and WL led the data collection and analysis. All authors drafted the text and\/or provided critical review of drafts and approved the final manuscript.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}}]}}